Core Viewpoint - Vivos Therapeutics, Inc. has made a significant acquisition of The Sleep Center of Nevada, which is expected to enhance its revenue generation and patient demand for its obstructive sleep apnea (OSA) treatments. The company is transitioning its business model to focus on direct patient relationships and sleep center alliances [1][3]. Financial Performance - For the second quarter of 2025, Vivos reported revenue of $3.8 million, a decrease from $4.1 million in the same period of 2024. For the six months ended June 30, 2025, revenue was $6.8 million compared to $7.5 million in 2024 [4]. - Gross profit for the second quarter of 2025 was $2.1 million, down from $2.7 million in the second quarter of 2024. For the six months ended June 30, 2025, gross profit was $3.6 million compared to $4.6 million in 2024 [4]. - The gross margin declined to 55% in the second quarter of 2025 from 65% in the same period of 2024, attributed to pricing discounts and the transition to a new sales model [4]. - Operating expenses increased by 52% to $7.0 million in the second quarter of 2025, compared to $4.6 million in the same period of 2024, largely due to costs associated with the acquisition and integration of SCN [4]. Strategic Initiatives - The acquisition of The Sleep Center of Nevada marks a strategic shift in Vivos' sales and marketing approach, moving from a dentist-reliant model to a more comprehensive model that includes direct patient engagement [3]. - Vivos is also developing a new sleep practice management model to partner with sleep centers that are not interested in acquisition but want to offer Vivos' OSA diagnostic and treatment options [5][6]. - The company is actively seeking additional sleep center alliances or acquisitions to scale its new model, as demand at SCN locations has exceeded current capacity [3]. Market Context - OSA affects over 1 billion people globally, with a significant portion remaining undiagnosed. This presents a substantial market opportunity for innovative treatments that address the root causes of OSA [11]. - Vivos' proprietary treatments, including the Complete Airway Repositioning and Expansion (CARE) devices, are FDA-cleared for various severity levels of OSA, positioning the company favorably in the medical device market [10].